Home / Intelligence / Blog / AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Published September 27, 2021
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies.
The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based on clinical trial data which suggests improved detection of cancer on slide images by an average of 7.3% with Paige Prostate vs. unassisted examination by pathologists. The program also reduced the number of false-negatives by 70% and false-positives by 24%. This FDA authorization follows Paige AI receiving a CE mark for both its prostate software and its breast cancer product for use in the EU last year.
Paige’s co-founder and chief medical officer, David Klimstra, notes that Paige’s landmark FDA-approval and EU access “marks the beginning of a new era in the use of computer-assisted diagnostics for pathology.”
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Webinars
The Future of Patient Finding
November 13, 2024 | 1:00 – 1:45 PM ET
Two additional sessions will be offered: November 14 – 16:00 – 16:45 (UTC +8:00) – Asia/Shanghai November 14 – 15:00 – 15:45 CET – Europe/Berlin Patient finding is more than a buzzword. Ready to challenge the status quo? With more data, advancements in AIML and greater access to insights, it is not surprising that patient […]
Sign Up Now
Case Studies
Improving Data Operations Efficiency through GenAI-Powered Process Automation
The Situation Pharmaceutical companies are mandated to cease all forms of engagement with debarred healthcare professionals (HCPs) in the U.S. Compliance entails identifying and flagging HCPs from lists periodically released by government agencies. These agencies also issue exclusion notices that call out HCPs whomight be confused with debarred HCPs due to similar names and/or other […]
Read More
Blog
The Next Wave of Global AI Medical Devices: Innovation in Action
A recent bipartisan initiative by Senators Martin Heinrich, Mike Rounds, Marsha Blackburn and Todd Young urged the Centers for Medicare & Medicaid Services (CMS) to establish a formal payment pathway for algorithm-based health care services (ABHS). This move addresses the need for stable Medicare reimbursement for FDA-cleared AI and machine learning (ML) medical devices, which […]
Read More